About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Oct 11, 2011...
“I believe there is real magic in the way thatembryos develop. I’ve been studying them for almost 15 years and Ihaven’t stopped being amazed,” says Dr. Karina Yaniv of the WeizmannInstitute of Science’s Department of Biological Regulation.
Dr. Yaniv focuses on examining how blood and lymphatic vessels formduring embryonic development. Her research may, in the future, lead tonew therapies for heart disease, stroke, cancer, and other illnesses. “Ithink it’s imperative for us to learn how to manipulate vessel growth,”she says. “Sometimes we want to encourage vessel growth and sometimeswe want to stop it.”
Mar 08, 2017...
Hockey player Sam Fields was diagnosed with cancer at age 27, just weeks before he was scheduled to go to NHL training camp. (Courtesy ICRF)
This story is sponsored by the Israel Cancer Research Fund.
CHICAGO — Hockey had been the focal point of Sam Fields’ life for almost as long as he can remember.
A Chicago native who got into the sport at the age of eight, Fields had been playing professional hockey for about five years when he was tapped for a tryout with the National Hockey League. At the age of 27, he was on the cusp of becoming one of a handful of Jews in the NHL.
https://www.weizmann-usa.org/news-media/feature-stories/repairing-dna-fighting-cancer/
Sep 17, 2018...
Prof. Zvi Livneh
Our genetic material – DNA – is under constant assault. It is damaged every day by external forces like sunlight, radiation, tobacco smoke, air pollution, and food additives, and internal ones like waste products left over from the body’s metabolic processes.
“The DNA of each cell in your body is damaged about 50,000 times each day,” says Prof. Zvi Livneh. “That’s a massive attack.”
Jan 05, 2004... Weizmann Institute scientists have succeeded in reversing the metastatic properties of colon cancer cells, in vitro. The findings, published in The Journal of Cell Biology, uncover a key process involved in the metastasis of colon cancer cells and raise hopes that target-specific drugs might be devised to prevent, or reverse, the invasive behavior of metastatic colon cancer cells. Colon cancer is the second most-prevalent type of cancer in men and third in women in the Western world.
https://www.weizmann-usa.org/news-media/video-gallery/israel-leads-in-prostate-cancer-research/
Jun 17, 2016... Reporter Natasha Kirtchuk describes the new prostate cancer treatment developed by the Weizmann Institute's Profs. Avigdor Scherz and Yoram Salomon, along with an extended team of scientists, researchers, oncologists, urologists, clinicians, technicians, and more. The therapy involves no radiation or chemotherapy, takes just 90 minutes to complete...
https://www.weizmann-usa.org/news-media/in-the-news/an-immune-system-trained-to-kill-cancer/
Sep 13, 2011...
CLOSE-UP Dr. Carl June examined re-engineered T-cells last week in his Philadelphia lab. Jessica Kourkounis for The New York Times
PHILADELPHIA — A year ago, when chemotherapy stopped working against his leukemia, William Ludwig signed up to be the first patient treated in a bold experiment at the University of Pennsylvania. Mr. Ludwig, then 65, a retired corrections officer from Bridgeton, N.J., felt his life draining away and thought he had nothing to lose.
Jan 04, 2016...
Magnetic resonance images of the prostate gland after treatment with TOOKAD® Soluble. The black regions show the portions of the prostate where cancer was identified and eliminated by the therapy.
REHOVOT, ISRAEL—January 4, 2016—A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech (Luxembourg) has been approved by Cofepris, Mexico’s health authority, for the focal treatment of early-stage prostate cancer.
Apr 29, 2019...
TOOKAD® optic fibers illuminate only the cancerous regions, leaving healthy tissue alone
REHOVOT, ISRAEL—April 29, 2019—Steba Biotech, a privately owned company, has, in collaboration with scientists at the Weizmann Institute of Science, conducted extensive research and development on the prostate cancer treatment TOOKAD® – and now has received marketing authorization to make it available in 31 European countries. Following this regulatory approval, the first patients are currently being treated in top Israeli, German, English, and Italian medical centers.
https://www.weizmann-usa.org/news-media/news-releases/science-tips-january-2007/
Jan 24, 2007...
Weizmann Institute Scientists Discover a Genetic Risk Factor for Smoking-linked Head and Neck Cancer
A simple blood test may be able to identify those most at risk for developing head and neck cancer as a result of smoking. This was the finding of a recent study by Prof. Zvi Livneh, Head of the Weizmann Institute’s Biological Chemistry Department, Dr. Tamar Paz-Elizur of the same department, and their research team that worked in collaboration with Dr. Rami Ben-Yosef of Tel Aviv-Sourasky Medical Center, Prof. Laurence Freedman of Sheba Medical Center and Prof. Edna Schechtman of Ben-Gurion University of the Negev.
Sep 23, 2019...
JERUSALEM, Sept. 23 (Xinhua) – Israeli and U.S. researchers found that glioblastoma brain cancer cells come in four states and can transition from one state to another, the Weizmann Institute of Science (WIS) in central Israel reported on Monday.
The study, published in the journal Cell, was led by researchers from WIS, Massachusetts General Hospital (MGH) in Boston and the Salk Institute for Biological Studies in La Jolla, California.
©2023 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR
